Jason Aldred, MD
Neurology · Spokane, WANPI 1003969684
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $777,975 of the $1,014,739 with a category attached, or 76.7%. 33 manufacturers reported payments, led by AbbVie at 39.8% of the total. Among neurology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,089 payments — averaging $931.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$404K
- Teva Pharmaceuticals USA, Inc.$373K
- Acorda Therapeutics, Inc$68K
- Boston Scientific$56K
- Neurocrine Biosciences, Inc.$47K
- Amneal Pharmaceuticals LLC$14K
- plus $52K from 27 others
Across 924 payments — averaging $9277.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$2M
- Biogen$1.7M
- AbbVie$1.5M
- Sage Therapeutics, LLC$714K
- Genentech, Inc.$478K
- H. Lundbeck A S$398K
- plus $1.8M from 18 others
What the payments were for
- Consulting fees$177,36417%
- Speaking & faculty fees$777,97577%
- Travel & lodging$39,1004%
- Food & beverage$15,5372%
- Education$4,7640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 313 | $404,049 |
| Teva Pharmaceuticals USA, Inc. | 292 | $373,298 |
| Acorda Therapeutics, Inc | 60 | $68,137 |
| Boston Scientific | 117 | $56,418 |
| Neurocrine Biosciences, Inc. | 68 | $47,445 |
| Amneal Pharmaceuticals LLC | 41 | $13,603 |
| Merz Pharmaceuticals, LLC | 26 | $12,496 |
| Sunovion Pharmaceuticals Inc. | 12 | $12,179 |
| Biogen | 18 | $11,540 |
| MDD US Operations, LLC | 16 | $7,476 |
| Kyowa Kirin, Inc. | 10 | $3,587 |
| Medtronic(2 entities) | 16 | $2,357 |
| Ipsen Biopharmaceuticals, Inc | 21 | $448 |
| Acadia Pharmaceuticals Inc | 20 | $389 |
| Sanofi | 9 | $160 |
| Novartis | 8 | $141 |
| GE HealthCare | 3 | $135 |
| EMD Serono, Inc. | 6 | $124 |
| Revance Therapeutics, Inc. | 4 | $121 |
| Merz North America, Inc. | 4 | $100 |
| Supernus Pharmaceuticals, Inc. | 4 | $91 |
| Abbott | 3 | $79 |
| Cala Health, Inc. | 3 | $71 |
| Lilly USA, LLC | 3 | $57 |
| Orphalan Inc | 2 | $50 |
| Lundbeck LLC | 2 | $47 |
| Amgen | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Zyla Life Sciences, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| GRT US Holding, Inc. | 1 | $16 |
| Strongbridge US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$216,186
- AUSTEDO$153,638
- BOTOX$119,177
- Duopa$97,391
- VYALEV$88,866
- INBRIJA$67,472
- INGREZZA$26,333
- VERCISE$26,193
- GENERAL DBS$18,031
- ONGENTYS$17,850
- KYNMOBI$12,155
- XEOMIN$11,893
- CREXONT$8,336
- GOCOVRI$4,185
- NOURIANZ$3,478
- RYTARY$2,800
- CROSSBOSS$2,550
- ACTIVA$2,000
- ONGENTYS 50MG CAPSULES 30$1,300
- GENERAL - THERAPIES$798
How this compares
$1,014,739 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 60 | $646,201 |
| NuplazidPimavanserin Tartrate | 110 | $598,006 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 31 | $393,106 |
| RytaryCarbidopa/Levodopa | 207 | $272,361 |
| IngrezzaValbenazine Tosylate | 33 | $264,690 |
| GocovriAmantadine Hcl | 68 | $260,189 |
| OngentysOpicapone | 64 | $48,804 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 627 | $42,027 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 911 | $34,561 |
| Rasagiline Mesylate | 186 | $33,539 |
| BriviactBrivaracetam | 24 | $31,609 |
| InbrijaLevodopa | 15 | $26,346 |
| Entacapone | 144 | $19,674 |
| AmantadineAmantadine Hcl | 194 | $14,636 |
| CrexontCarbidopa/Levodopa | 18 | $13,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $373,298 | $646,20160 claims |
| Acadia Pharmaceuticals IncNuplazid | $389 | $598,006110 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $47,445 | $313,49497 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $13,603 | $285,390225 claims |
| MDD US Operations, LLCGocovri | $7,476 | $260,18968 claims |
| Acorda Therapeutics, IncInbrija | $68,137 | $26,34615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 neurology providers in Washington.
Other neurology in Spokane
- Jessica CraddockSpokane$266K
- Steven PughSpokane$162K
- Luis ParySpokane$64K
- David GreeleySpokane$39K
- Pavle RepovicSeattle$1.1M
- Pinky AgarwalKirkland$795K
- Stacy DonlonTacoma$613K
- Nathaniel WatsonSeattle$486K
- James BowenKirkland$379K
- Christyn EdmundsonSeattle$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.